Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7003851 | 0.97 | ABCC8 (0.31) | ABCC8KCNJ11 | |
| SCHEMBL7000793 | 0.96 | ABCC8 (0.30) | ABCC8KCNJ11 | |
| SCHEMBL6791354 | 0.94 | ABCC8 (0.31) | ABCC8KCNJ11 | |
| SCHEMBL6996322 | 0.83 | — | — | |
| SCHEMBL7004764 | 0.80 | ABCC8 (0.31) | ABCC8KCNJ11 | |
| SCHEMBL7067549 | 0.79 | — | — | |
| SCHEMBL7000381 | 0.78 | JAK2 (0.31) | — | |
| SCHEMBL7006346 | 0.74 | — | — | |
| SCHEMBL7066423 | 0.74 | ABCC8 (0.31) | ABCC8KCNJ11 | |
| SCHEMBL7068004 | 0.74 | HTR5A (0.35) | ABCC8KCNJ11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003105896-A1 | COMBINED USE OF A MODULATOR OF CD3 AND A BETA CELL RESTING COMPOUND | NOVO NORDISK A/S (DK) | 2003-12-24 | — | — | WO | claimed |
| WO-2003045954-A1 | USE OF SELECTIVE POTASSIUM CHANNEL OPENERS | NOVO NORDISK A/S (DK) | 2003-06-05 | — | — | WO | claimed |
| WO-2003045955-A1 | USE OF SELECTIVE POTASSIUM CHANNEL OPENERS | NOVO NORDISK A/S (DK) | 2003-06-05 | — | — | WO | claimed |
| EP-1140945-B1 | FUSED 1,2,4-THIADIAZINE DERIVATIVES, THEIR PREPARATION AND USE | NOVO NORDISK AS (DK) | 2003-06-04 | — | — | EP | claimed |
| WO-2002000222-A1 | USE OF POTASSIUM CHANNEL AGONISTS FOR THE TREATMENT OF CANCER | NOVO NORDISK A/S (DK) | 2002-01-03 | — | — | WO | claimed |
| WO-2002000223-A1 | USE OF POTASSIUM CHANNEL AGONISTS FOR REDUCING FAT FOOD COMSUMPTION | NOVO NORDISK A/S (DK) | 2002-01-03 | — | — | WO | claimed |
| EP-1140945-A1 | FUSED 1,2,4-THIADIAZINE DERIVATIVES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2001-10-10 | — | — | EP | claimed |
| WO-2000037474-A1 | FUSED 1,2,4-THIADIAZINE DERIVATIVES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-06-29 | — | — | WO | claimed |
| WO-2003105896-A1 | COMBINED USE OF A MODULATOR OF CD3 AND A BETA CELL RESTING COMPOUND | NOVO NORDISK A/S (DK) | 2003-12-24 | — | — | WO | disclosed |
| WO-2003045954-A1 | USE OF SELECTIVE POTASSIUM CHANNEL OPENERS | NOVO NORDISK A/S (DK) | 2003-06-05 | — | — | WO | disclosed |
| WO-2003045955-A1 | USE OF SELECTIVE POTASSIUM CHANNEL OPENERS | NOVO NORDISK A/S (DK) | 2003-06-05 | — | — | WO | disclosed |
| WO-2002000222-A1 | USE OF POTASSIUM CHANNEL AGONISTS FOR THE TREATMENT OF CANCER | NOVO NORDISK A/S (DK) | 2002-01-03 | — | — | WO | disclosed |
| WO-2002000223-A1 | USE OF POTASSIUM CHANNEL AGONISTS FOR REDUCING FAT FOOD COMSUMPTION | NOVO NORDISK A/S (DK) | 2002-01-03 | — | — | WO | disclosed |
| EP-1140945-A1 | FUSED 1,2,4-THIADIAZINE DERIVATIVES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000037474-A1 | FUSED 1,2,4-THIADIAZINE DERIVATIVES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-06-29 | — | — | WO | disclosed |